MicroRNA‑136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen‑activated protein kinase kinase 4 Retraction in /10.3892/mmr.2023.13003

Zhu,Yudi; Shao,Siliang; Pan,Huafeng; Cheng,Zhongliang; Rui,Xin

doi:10.3892/mmr.2018.8417

MicroRNA‑136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen‑activated protein kinase kinase 4

Retraction in: /10.3892/mmr.2023.13003

Authors:
- Yudi Zhu
- Siliang Shao
- Huafeng Pan
- Zhongliang Cheng
- Xin Rui
View Affiliations

Affiliations: Department of Urology, Ningbo No. 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang 315010, P.R. China
Published online on: January 10, 2018 https://doi.org/10.3892/mmr.2018.8417
Pages: 4803-4810

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is the second most common type of cancer and the 6th leading cause of cancer‑associated mortality worldwide. Accumulated evidence suggests that PCa initiation and progression are controlled by microRNAs (miRNAs). Therefore, investigating PCa‑associated miRNAs may provide novel biomarkers for the diagnosis and treatment of patients with PCa. In the present study it was demonstrated that miRNA‑136 (miR‑136) expression was significantly downregulated in PCa tissues and cell lines. The resumption of miR‑136 expression suppressed cell proliferation and invasion in PCa cells. Bioinformatics analysis predicted that mitogen‑activated protein kinase kinase 4 (MAP2K4) was a direct target of miR‑136. This prediction was experimentally confirmed by a luciferase reporter assay, RT‑qPCR and western blot analysis. MAP2K4 was highly expressed in PCa tissues and inversely correlated with the miR‑136 expression level. Additionally, the restoration of MAP2K4 expression significantly blocked the inhibitory effects of miR‑136 on cell proliferation and invasion in PCa cells. Therefore, miR‑136 may suppress the proliferation and invasion of PCa cells by targeting MAP2K4 and may be a novel candidate target for cancer therapy against PCa.

View Figures

View References

1	Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, Wang G, Liu Z and Debré B: A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 16:4472–4477. 2009.PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Wu D, Zhou Y, Pan H, Qu P and Zhou J: MicroRNA99a inhibits cell proliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer. Mol Med Rep. 11:1469–1475. 2015. View Article : Google Scholar : PubMed/NCBI
5	Rubin MA, Maher CA and Chinnaiyan AM: Common gene rearrangements in prostate cancer. J Clin Oncol. 29:3659–3668. 2011. View Article : Google Scholar : PubMed/NCBI
6	Deng X, He G, Liu J, Luo F, Peng X, Tang S, Gao Z, Lin Q, Keller JM, Yang T and Keller ET: Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev. 40:730–738. 2014. View Article : Google Scholar : PubMed/NCBI
7	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
8	Souza AG, Bastos VAF, Silva IBB, Marangoni K and Goulart VA: Different gene therapy strategies: A overview for prostate cancer. Curr Gene Ther. 16:287–291. 2016. View Article : Google Scholar : PubMed/NCBI
9	Koupparis A and Gleave ME: Multimodal approaches to high-risk prostate cancer. Curr Oncol. 17 Suppl 2:S33–S37. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lee YS and Dutta A: MicroRNAs: Small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs. 7:560–564. 2006.PubMed/NCBI
11	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
12	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI
13	Fazi F and Blandino G: MicroRNAs: Non coding pleiotropic factors in development, cancer prevention and treatment. Microrna. 2:812013. View Article : Google Scholar : PubMed/NCBI
14	Massillo C, Dalton GN, Farré PL, De Luca P and De Siervi A: Implications of microRNA dysregulation in the development of prostate cancer. Reproduction. 154:R81–R97. 2017. View Article : Google Scholar : PubMed/NCBI
15	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261. 2006; View Article : Google Scholar : PubMed/NCBI
16	Spizzo R, Nicoloso MS, Croce CM and Calin GA: SnapShot: MicroRNAs in cancer. Cell. 137:586. 2009. View Article : Google Scholar : PubMed/NCBI
17	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
18	Zheng J, Ge P, Liu X, Wei J, Wu G and Li X: miR-136 inhibits gastric cancer-specific peritoneal metastasis by targeting HOXC10. Tumour Biol. 39:10104283177062072017. View Article : Google Scholar : PubMed/NCBI
19	Yan M, Li X, Tong D, Han C, Zhao R, He Y and Jin X: miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncol Rep. 36:65–71. 2016. View Article : Google Scholar : PubMed/NCBI
20	Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu Q, Cao K and Li Q: miR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J Neurooncol. 120:43–53. 2014. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Pavese JM, Ogden IM, Voll EA, Huang X, Xu L, Jovanovic B and Bergan RC: Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One. 9:e1022892014. View Article : Google Scholar : PubMed/NCBI
23	Wan X, Huang W, Yang S, Zhang Y, Zhang P, Kong Z, Li T, Wu H, Jing F and Li Y: Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression. Int J Biochem Cell Biol. 79:249–260. 2016. View Article : Google Scholar : PubMed/NCBI
24	Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, Stadler W and Rinker-Schaeffer CW: Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: An important role for SAPK signalling in prostatic neoplasia. J Pathol. 212:386–394. 2007. View Article : Google Scholar : PubMed/NCBI
25	Sun Y, Jia X, Hou L and Liu X: Screening of differently expressed miRNA and mRNA in prostate cancer by integrated analysis of transcription data. Urology. 94:313.e1–e6. 2016. View Article : Google Scholar
26	Wang Z, Xu L, Hu Y, Huang Y, Zhang Y, Zheng X, Wang S, Wang Y, Yu Y, Zhang M, et al: miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer. Sci Rep. 6:256022016. View Article : Google Scholar : PubMed/NCBI
27	Li JZ, Li J, Wang HQ, Li X, Wen B and Wang YJ: miR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 482:1381–1386. 2017. View Article : Google Scholar : PubMed/NCBI
28	Jeong JY, Kang H, Kim TH, Kim G, Heo JH, Kwon AY, Kim S, Jung SG and An HJ: MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett. 386:168–178. 2017. View Article : Google Scholar : PubMed/NCBI
29	Yuan Q, Cao G, Li J, Zhang Y and Yang W: MicroRNA-136 inhibits colon cancer cell proliferation and invasion through targeting liver receptor homolog-1/Wnt signaling. Gene. 628:48–55. 2017. View Article : Google Scholar : PubMed/NCBI
30	Wang JJ, Li ZF, Li XJ, Han Z, Zhang L and Liu ZJ: Effects of microRNA-136 on melanoma cell proliferation, apoptosis, and epithelial-mesenchymal transition by targetting PMEL through the Wnt signaling pathway. Biosci Rep. 37:BSR201707432017. View Article : Google Scholar : PubMed/NCBI
31	Shen S, Yue H, Li Y, Qin J, Li K, Liu Y and Wang J: Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumour Biol. 35:631–640. 2014. View Article : Google Scholar : PubMed/NCBI
32	Yang Y, Wu J, Guan H, Cai J, Fang L, Li J and Li M: MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
33	Wu H, Liu Q, Cai T, Chen YD, Liao F and Wang ZF: MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1. Diagn Pathol. 9:1732014. View Article : Google Scholar : PubMed/NCBI
34	Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo G, Jiang J and Cui S: Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep. 33:591–598. 2015. View Article : Google Scholar : PubMed/NCBI
35	Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM and Rinker-Schaeffer CW: Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 59:5483–5487. 1999.PubMed/NCBI
36	Tesser-Gamba F, Petrilli AS, de Seixas Alves MT, Filho RJ, Juliano Y and Toledo SR: MAPK7 and MAP2K4 as prognostic markers in osteosarcoma. Hum Pathol. 43:994–1002. 2012. View Article : Google Scholar : PubMed/NCBI
37	Wu X, Gong Z, Sun L, Ma L and Wang Q: MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4. Cell Prolif. 50:2017. View Article : Google Scholar
38	Liu S, Liu YY and Li R: Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer. Nan Fang Yi Ke Da Xue Xue Bao. 37:488–493. 2016.(In Chinese). PubMed/NCBI
39	Wang L, Pan Y and Dai JL: Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene. 23:5978–5985. 2004. View Article : Google Scholar : PubMed/NCBI
40	Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N and Miyazaki K: MKK4 acts as a potential tumor suppressor in ovarian cancer. Tumour Biol. 32:661–670. 2011. View Article : Google Scholar : PubMed/NCBI
41	Ishikawa M, Nakayama K, Rahman MT, Rahman M, Katagiri A, Iida K and Miyazaki K: Functional and clinicopathological analysis of loss of MKK4–– expression in endometrial cancer. Oncology. 79:238–246. 2010. View Article : Google Scholar : PubMed/NCBI